- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02197715
Sex and Female Empowerment (SAFE)
13. Oktober 2017 aktualisiert von: University of North Carolina, Chapel Hill
Improving Women's Sexual Health While in Drug Addiction Treatment
This study will develop and initially evaluate Sex and Female Empowerment (SAFE), an intervention designed to increase acceptance of and adherence to contraceptive practices among opioid-agonist-maintained women of childbearing age.
The intervention will be delivered in one of two formats: a face-to-face brief intervention approach or a novel computer-adaptive platform.
To the extent that either version of SAFE is found to be efficacious compared with usual care, it has the potential to reduce the number of unintended pregnancies and consequently decrease the need for and the costs of child protective services.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
90
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- UNC Horizons
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 40 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Weiblich
Beschreibung
Inclusion criteria will be:
- ages 18-40 years old for women;
- able to provide informed consent;
- currently enrolled in a opioid-agonist-maintenance program;
- currently not pregnant (urine testing confirmation);
- report heterosexual orientation;
- no tubal ligation or other sterilization;
- no plans to become pregnant in the next 6 months; and
- provides verifiable locator information.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: computer-adaptive SAFE
Computer-adaptive SAFE will consist of 4 60-minute sessions.
Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods.
Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method.
Session 4 will focus on effective strategies to communicate with a sexual partner.
Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
|
|
|
Experimental: Face-to-face SAFE
Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques.
Each session will be led by an experienced counselor.
Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods.
Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods.
Session 4 will focus on effective strategies to communicate with a sexual partner.
|
|
|
Aktiver Komparator: Usual Care
Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods.
Contraceptive methods are discussed within this context.
There will be no demand on participants to attend these sessions.
Participants will receive written take-home materials to review on their own and/or with their sex partners.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Intervention Satisfaction
Zeitfenster: The earlier of the completion of the 4 interventions sessions or 6 weeks.
|
Summary scale score: Derived from responses to a four-item 5-point Likert-type scale (1 = "not at all help" to 5 = "extremely helpful") of satisfaction with the intervention, administered at the end of each of the four intervention sessions.
|
The earlier of the completion of the 4 interventions sessions or 6 weeks.
|
|
Contraceptive Consultation Appointment
Zeitfenster: The earlier of the completion of the 4 intervention sessions or 6 weeks.
|
Binary variable: Did or did not the participant schedule and attend an appointment with a obstetrical provider at University of North Carolina at Chapel Hill Obstetrical/Gynecological Services, determined from medical records.
|
The earlier of the completion of the 4 intervention sessions or 6 weeks.
|
|
Intervention Completion
Zeitfenster: The earlier of the completion of the 4 interventions sessions or 6 weeks.
|
Binary variable: Completes or fails to complete all four intervention sessions in a 6-week period, determined from study records.
|
The earlier of the completion of the 4 interventions sessions or 6 weeks.
|
|
Contraceptive Method Effectiveness
Zeitfenster: The earlier of the completion of the 4 intervention sessions or 6 weeks.
|
Percentage: The typical use effectiveness level of the contraceptive method in use at the end of the intervention based on responses to the National Survey of Family Growth contraceptive methods items.
If the participant does not make an appointment and choose a contraceptive method, the typical-use effectiveness level of the contraceptive method indicated at intake in response to the Survey of Family Growth contraceptive methods items will be used.
Typical effectiveness rating of contraceptive methods is a percentage between 15% and 99.85%, and will be based on Hatcher, R.A., Contraceptive technology, which reports success and failure rates for contraceptive methods in current use.
|
The earlier of the completion of the 4 intervention sessions or 6 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Knowledge of Reproduction
Zeitfenster: Baseline, 1-, 3-, and 6-months post-baseline
|
Summary scale score: Derived from eight true-false questions about participants' understanding of the information that was presented in the four intervention sessions about anatomy, menstruation, fertility, and conception, administered at each assessment time point.
|
Baseline, 1-, 3-, and 6-months post-baseline
|
|
Knowledge of Contraceptive Methods
Zeitfenster: Baseline, 1-, 3-, 6-months post-baseline
|
Summary scale score: Derived from twenty true-false questions about participants' understanding of the information presented in the four intervention sessions about contraceptive methods, how hormonal contraceptives work, how to correctly use them; hormonal contraceptive side effects and ways to deal with them; which methods are effective against STIs/HIV; correct condom use, administered at each assessment time point.
|
Baseline, 1-, 3-, 6-months post-baseline
|
|
Contraceptive Self-efficacy Scale
Zeitfenster: Baseline, 1-, 3-, and 6-months post-baseline
|
Summary scale score: Derived from the Contraceptive Self-efficacy Scale, an eighteen-item 5-point Likert-type scale (1 = "not at all true of me" and 5 = "completely true of me") designed to measure a female respondent's motivational barriers to effective contraceptive use, including obtaining contraceptives, using contraceptives with a partner, talking to a partner about contraceptive use, using contraceptives despite partner approval, and preventing unprotected sexual intercourse, administered at each assessment time point.
|
Baseline, 1-, 3-, and 6-months post-baseline
|
|
Effective Contraceptive Behavior
Zeitfenster: Baseline, 1-, 3-, and 6-months post-baseline
|
Ordered polytomous variable: Participant's self-report of their contraceptive behavior obtained at each assessment time point will be classified into 1 of 4 patterns: (1) "uninterrupted effective user" (e.g., implant, injectable, an IUD); (2) "uninterrupted other user" (use of effective methods on an interrupted basis); (3) "sporadic user" (use of some method when at risk for pregnancy); or (4) "nonuser", where "uninterrupted" in (1) means that an effective method was used for the entire time period under assessment; otherwise, categorized as (2).
|
Baseline, 1-, 3-, and 6-months post-baseline
|
|
Frequency of Use of Barrier Protection in past 30 days
Zeitfenster: Baseline, 1-, 3-, and 6-months post-baseline
|
Count variable: Self-reported number of times in the past 30 days a participant used a barrier method for protection from HIV/STIs when engaging in sexual activities, collected at each assessment time point.
|
Baseline, 1-, 3-, and 6-months post-baseline
|
|
Number of Times Engaged in Unprotected Sex in past 30 days
Zeitfenster: Baseline, 1-, 3-, and 6-months post-baseline
|
Count variable: Self-reported number of times in the past 30 days a participant engaged in unprotected vaginal, oral, or anal sex, collected at each assessment time point.
|
Baseline, 1-, 3-, and 6-months post-baseline
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Mitarbeiter
Ermittler
- Hauptermittler: Hendrée E Jones, PhD, University of North Carolina, Chapel Hill
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. August 2014
Primärer Abschluss (Tatsächlich)
1. August 2017
Studienabschluss (Tatsächlich)
1. August 2017
Studienanmeldedaten
Zuerst eingereicht
21. Juli 2014
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
21. Juli 2014
Zuerst gepostet (Schätzen)
23. Juli 2014
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
17. Oktober 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. Oktober 2017
Zuletzt verifiziert
1. Oktober 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 13-3075
- R34DA033442 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .